Article from the Symposium

You have full text access to this OnlineOpen article

Role of stromal-derived cytokines and growth factors in bone metastasis

  1. G. David Roodman M.D., Ph.D.†,*

Article first published online: 23 JAN 2003

DOI: 10.1002/cncr.11148

Issue

Cancer

Cancer

Supplement: Skeletal Complications of Malignancy

Volume 97, Issue Supplement 3, pages 733–738, 1 February 2003

Additional Information

How to Cite

David Roodman, G. (2003), Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer, 97: 733–738. doi: 10.1002/cncr.11148

Author Information

  1. School of Medicine/Hematology-Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania

  1. †

    Fax: (412) 648-9723

*School of Medicine/Hematology-Oncology, University of Pittsburgh, E-1152 BSTWR, 200 Lothrop Street, Pittsburgh, PA 15213

Publication History

  1. Issue published online: 23 JAN 2003
  2. Article first published online: 23 JAN 2003
  3. Manuscript Accepted: 1 NOV 2002
  4. Manuscript Received: 15 JUL 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (141K)

REFERENCES

  • 1
    van der Pluijm G, Sijmons B, Vloedgraven H, et al. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol. 2001; 159: 971–982.
  • 2
    Sung V, Stubbs JT III, Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol. 1998; 176: 482–494.
    Direct Link:
  • 3
    Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma [review]. Leuk Lymphoma. 2000; 38: 71–81.
  • 4
    Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest. 2001; 108: 1833–1841.
  • 5
    Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000; 96: 671–675.
  • 6
    Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1 alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappa B ligand. Blood. 2001; 97: 3349–3353.
  • 7
    Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases [review]. Crit Rev Eukaryot Gene Expr. 2000; 10: 159–178.
  • 8
    Festuccia C, Bologna M, Gravina GL, et al. Osteoblast conditioned media contain TGF-beta 1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer. 1999; 81: 395–403.
    Direct Link:
  • 9
    Lang SH, Clarke NW, George NJ, Testa NG. Scatter factor influences the formation of prostate epithelial cell colonies on bone marrow stroma in vitro. Clin Exp Metast. 1999; 17: 333–340.
  • 10
    Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001; 98: 2992–2998.
  • 11
    Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996; 98: 1544–1549.
  • 12
    Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999; 103: 197–206.
  • 13
    Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res. 2002; 62: 917–923.
  • 14
    Chikazu D, Katagiri M, Ogasawara T, et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J Bone Mineral Res. 2001; 16: 2074–2081.
    Direct Link:
  • 15
    Beck D, Gross N, Beretta Brognara C. Effects of stem cell factor and other bone marrow-derived growth factors on the expression of adhesion molecules and proliferation of human neuroblastoma cells. Eur J Cancer. 1995; 31A: 467–470.
  • 16
    Niida S, Kaku M, Amano H, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med. 1999; 190: 293–298.
  • 17
    Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001; 15: 1950–1961.
  • 18
    Shinar DM, Endo N, Halperin D, Rodan GA, Weinreb M. Differential expression of insulin-like growth factor-I (IGF-I) and IGF-II messenger ribonucleic acid in growing rat bone. Endocrinology. 1993; 132: 1158–1167.
  • 19
    Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol. 2000; 111: 626–634.
  • 20
    Kurihara, Bertolini D, Suda T, Akiyama Y, Roodman GD. Interleukin-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing interleukin-1. J Immunol. 1990; 144: 4226–4230.
  • 21
    Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996; 87: 1104–1112.
  • 22
    Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002; 116: 278–290.
    Direct Link:
  • 23
    Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res. 2001; 100: 18–24.
  • 24
    Oyajobi BO, Williams PJ, Story B, Mundy GR. Myeloma bone disease and tumor burden reversed by a neutralizing antibody to macrophage inflammatory protein (MIP 1-α/CCL3) in vivo. J Bone Miner Res. 2001; 16 (Suppl 1): S192.
  • 25
    Vanderkerken K, Broek IV, Eizirik DL, et al. Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metast. 2002; 19: 87–90.
  • 26
    Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410: 50–56.
  • 27
    Geminder H, Sagi-Assif O, Goldberg L, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol. 2001; 167: 4747–4757.
  • 28
    Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1 alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood. 2001; 97: 346–351.
View Full Article (HTML) Get PDF (141K)